'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. (Q39136403)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

title

'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

3

Steven A Rosenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Eric Tran

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Paul F Robbins

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

English

0 references

publication date

1 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

255-262

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

2 April 2020

cites work

1 reference

MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases

21 January 2018

1 reference

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

21 January 2018

1 reference

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Understanding and learning from the success of prophylactic human papillomavirus vaccines.

21 January 2018

1 reference

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

21 January 2018

1 reference

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

21 January 2018

1 reference

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation

21 January 2018

1 reference

Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide

21 January 2018

1 reference

Tum- antigens, TSTA, and T cell immune surveillance

21 January 2018

1 reference

A unique tumor antigen produced by a single amino acid substitution

21 January 2018

1 reference

The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68

21 January 2018

1 reference

Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens

21 January 2018

1 reference

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

Exploiting the mutanome for tumor vaccination.

21 January 2018

1 reference

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

21 January 2018

1 reference

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

21 January 2018

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

21 January 2018

1 reference

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

21 January 2018

1 reference

T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product

21 January 2018

1 reference

Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy

21 January 2018

1 reference

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

21 January 2018

1 reference

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

21 January 2018

1 reference

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

21 January 2018

1 reference

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

21 January 2018

1 reference

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

21 January 2018

1 reference

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma

21 January 2018

1 reference

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck

21 January 2018

1 reference

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

21 January 2018

1 reference

The Immune Biology of Microsatellite-Unstable Cancer

21 January 2018

1 reference

Immunogenicity of somatic mutations in human gastrointestinal cancers.

21 January 2018

1 reference

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

21 January 2018

1 reference

Paths to stemness: building the ultimate antitumour T cell.

21 January 2018

1 reference

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

21 January 2018

1 reference

Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism

21 January 2018

1 reference

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

21 January 2018

1 reference

Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells

21 January 2018

1 reference

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.

21 January 2018

1 reference

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

21 January 2018

1 reference

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

Generation of peptide–MHC class I complexes through UV-mediated ligand exchange

21 January 2018

1 reference

7 January 2021

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.

1 reference

7 January 2021

Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.

1 reference

7 January 2021

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1 reference

7 January 2021

High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival

1 reference

12 December 2020

A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma

1 reference

12 December 2020

An antigen recognized by autologous CTLs on a human bladder carcinoma

1 reference

12 December 2020

The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NI.3682

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28198830%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference